Evidence map›Paper›PMID 26708710›Full record

ArticleActa biomaterialia2016

Intrinsic immunogenicity of rapidly-degradable polymers evolves during degradation.

James I Andorko, Krystina L Hess, Kevin G Pineault, Christopher M Jewell

Open access · hybridAbstract read
In one paragraph

Article in Acta biomaterialia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Biomacromolecules · 2025
    Review
  6. Review
  7. Review
  8. In vivo gene delivery to immune cells.Current opinion in biotechnology · 2024
    Review
  9. Review
  10. Review
  11. Engineering metabolism to modulate immunity.Advanced drug delivery reviews · 2024
    Review
  12. Review
  13. Review
  14. Review
  15. Poly(3-hydroxybutyrate) 3D-Scaffold-Conduit for Guided Tissue Sprouting.International journal of molecular sciences · 2023
    Article
  16. Challenges to Safe Nanomedicine Treatment.Nanomaterials (Basel, Switzerland) · 2023
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

James I AndorkoFischell Department of Bioengineering, University of Maryland, College Park, MD, United States.
Krystina L HessFischell Department of Bioengineering, University of Maryland, College Park, MD, United States.
Kevin G PineaultFischell Department of Bioengineering, University of Maryland, College Park, MD, United States.
Christopher M JewellFischell Department of Bioengineering, University of Maryland, College Park, MD, United States; Department of Microbiology and Immunology, University of Maryland Medical School, Baltimore, MD, United States; Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, United States. Electronic address: cmjewell@umd.edu.
University of Maryland, College Park · USUniversity of Maryland, Baltimore · US

Funding

Training in Host-pathogens interactionsT32AI089621 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LEE, VINCENT T, MCIVER, KEVIN S. · 2010 to 2025
$2.1M
NIAID NIH HHS T32 AI089621
6 · The paper itself

Abstract

Recent studies reveal many biomaterial vaccine carriers are able to activate immunostimulatory pathways, even in the absence of other immune signals. How the changing properties of polymers during biodegradation impact this intrinsic immunogenicity is not well studied, yet this information could contribute to rational design of degradable vaccine carriers that help direct immune response. We use degradable poly(beta-amino esters) (PBAEs) to explore intrinsic immunogenicity as a function of the degree of polymer degradation and polymer form (e.g., soluble, particles). PBAE particles condensed by electrostatic interaction to mimic a common vaccine approach strongly activate dendritic cells, drive antigen presentation, and enhance T cell proliferation in the presence of antigen. Polymer molecular weight strongly influences these effects, with maximum stimulation at short degradation times--corresponding to high molecular weight--and waning levels as degradation continues. In contrast, free polymer is immunologically inert. In mice, PBAE particles increase the numbers and activation state of cells in lymph nodes. Mechanistic studies reveal that this evolving immunogenicity occurs as the physicochemical properties and concentration of particles change during polymer degradation. This work confirms the immunological profile of degradable, synthetic polymers can evolve over time and creates an opportunity to leverage this feature in new vaccines. STATEMENT OF SIGNIFICANCE: Degradable polymers are increasingly important in vaccination, but how the inherent immunogenicity of polymers changes during degradation is poorly understood. Using common rapidly-degradable vaccine carriers, we show that the activation of immune cells--even in the absence of other adjuvants--depends on polymer form (e.g., free, particulate) and the extent of degradation. These changing characteristics alter the physicochemical properties (e.g., charge, size, molecular weight) of polymer particles, driving changes in immunogenicity. Our results are important as many common biomaterials (e.g., PLGA) are now known to exhibit immune activity that alters how vaccines are processed. Thus, the results of this study could contribute to more rational design of biomaterial carriers that also actively direct the properties of responses generated by vaccines.

Indexed as

AnimalsAntigen PresentationCell ProliferationDendritic CellsFemaleHistocompatibility Antigens Class IHistocompatibility Antigens Class IIImmunityMice, Inbred C57BLMolecular WeightPolymersT-LymphocytesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIpoly(beta-amino ester)PolymersDendritic cellImmune response and inflammationMicroparticle and nanoparticlePoly(beta-amino esters)Vaccine

Identifiers

PMID26708710
PMCPMC4754144
OpenAlexW2215597534

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.